immunotherapy | malecare.org

Towards An Understanding Of The Possible Future Role Of Combining Chemotherapy With Immunotherapy – On The Horizon

There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled "Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy." The study was conducted at the University of California, San Diego. Prostate cancers [...]

By Malecare|2017-10-19T10:47:20-04:00May 29th, 2015|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials & Research, Combination Therapy, Immunosuppressive B cells, oxaliplatin, Research, Uncategorized|0 Comments

A Real Role for Immunotherapy in the Treatment of Advanced Prostate Cancer

Immunotherapy has a major and expanding role in the treatment of cancer, including advanced prostate cancer. Over time there have been a number of naysayers as the immunotherapy Provenge has played the role whipping boy by critics. The common criticism leveled at Provenge can be summed up simply, “It doesn’t work.” The plain truth is [...]

By Malecare|2017-10-19T10:47:29-04:00March 26th, 2015|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, immunotherapy, ipilimumab, Prostvac, Uncategorized, vaccines, Yervoy|3 Comments

Malecare Adds A New Teleconference About Immunotherapy and Advanced Prostate Cancer

Malecare announces the addition of our latest and informative teleconference about Immunotherapy and Advanced Prostate Cancer. Joining me in the conference is Dr. Nicholas J. Vogelzang, M.D., a medical oncologist with the Comprehensive Cancer Centers of Nevada (CCCN) and serves as chair and site research leader, and as medical director of the Developmental Therapeutics Committee and Member [...]

By Malecare|2023-07-08T15:52:28-04:00April 28th, 2014|Advanced Prostate Cancer, Drugs & Treatments, General Information, immunotherapy, ipilimumab, Prostvac, Provenge, teleconferences, vaccines|1 Comment

Yervoy (ipilimumab) Fails to Extend Survival in Men with mCRP Who Failed Chemo

Some bad news was reported today. Results from the Phase 3 randomized, double-blind clinical trial (Study 043) comparing Yervoy 10 mg/kg (ipilimumab) (n=399) to placebo (n=400) following radiation in men with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel showed no increase in overall survival. Yervoy is an immunotherapy which [...]

By Malecare|2017-10-19T10:49:29-04:00September 12th, 2013|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, ipilimumab, Uncategorized, Understanding APC, Yervoy|0 Comments

Worthy New Immunotherapy Clinical Trial Opens at Johns Hopkins University for Men Thinking of Surgery

The exciting thing about Provenge is not only the real survival advantage that it offers with minimal side effects, but that it is a proof of concept treatment that is heralding in the potential future of many other immunotherapies. Today, we have two new possible treatments in active phase 3 trials, Prostvac and Yervoy. [...]

By Malecare|2021-02-17T10:43:31-05:00August 19th, 2013|Advanced Prostate Cancer, Bio Chemical Recurrence, Clinical Trials, Clinical Trials, GVAC, Uncategorized, vaccines|0 Comments